Sugi Predict

Sugi Predict / Compounds / SCHEMBL6344688

SCHEMBL6344688

SCHEMBL6344688

Oc1ccc(-c2cc[nH]n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ ESR1 P03372 4/20 0.43
▸ ESR2 Q92731 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ ALPL P05186 1/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30520597 0.98 MAPT (0.45) MAPTALDH1A1POLBHPGDHSD17B10
SCHEMBL4085552 0.90 ESR2 (0.52) MAPTALDH1A1POLBHPGDHSD17B10
SCHEMBL16766999 0.88 LMNA (0.36) MAPTPOLBMEN1KMT2ANPC1
SCHEMBL1645103 0.77 METAP2 (0.50) MAPTCA12ALPLMEN1KMT2A
SCHEMBL2765284 0.77 KMT2A (0.52) MAPTALDH1A1POLBHSD17B10ALPL
SCHEMBL8486152 0.77 LMNA (0.35) MEN1KMT2A
SCHEMBL989177 0.77 CA12 (0.42) MAPTALDH1A1POLBCA12ALPL
SCHEMBL9955 0.77 METAP2 (0.50) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL1260621 0.77 LMNA (0.32) MEN1KMT2A
SCHEMBL1926319 0.77 METAP2 (0.50) MAPTALDH1A1HPGDHSD17B10ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 — — US claimed
CN-119350639-A Micron-scale stable trimetallic MOF oxygen evolution catalyst and preparation method and application thereof 浙江工业大学 2025-01-24 — — CN disclosed
CN-115605596-A Compositions and methods for inducible alternative splicing modulation of gene expression 费城儿童医院（US） 2023-01-13 — — CN disclosed
CN-110015984-A Substituted (E)-N '-(1- phenylethylene) benzoyl hydrazine analog as histone demethylase inhibitor 犹他大学研究基金会 2019-07-16 — — CN disclosed
CN-105555784-B Substituted (E) -N' - (1-phenylethylene) benzoyl hydrazine analogs as histone demethylase inhibitors 犹他大学研究基金会 2019-03-15 — — CN disclosed
EP-2266960-B1 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants EURO CELTIQUE SA (LU) 2014-01-22 — — EP disclosed
CN-101172983-A Substituted phenylacetic acids METABOLEX INC (US) 2008-05-07 — — CN disclosed
CN-100338073-C Substituted phenylacetic acids METABOLEX INC (US) 2007-09-19 — — CN disclosed
CN-1653073-A Substituted phenylacetic acids METABOLEX INC (US) 2005-08-10 — — CN disclosed
US-6919460-B2 Processes and intermediates useful in preparing β3-adrenergic receptor agonists PFIZER INC, (US) 2005-07-19 — — US disclosed
EP-1478625-A1 PROCESSES AND INTERMEDIATES USEFUL IN PREPARING BETA-3-ADRENERGIC RECEPTOR AGONISTS Pfizer Products Inc. (US) 2004-11-24 — — EP disclosed
US-20040077871-A1 Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists PFIZER INC 2004-04-22 — — US disclosed
US-6689888-B2 Processes and intermediates useful in preparing β3-adrenergic receptor agonists PFIZER INC. 2004-02-10 — — US disclosed
US-20030199046-A1 Processes and intermediates useful in preparing beta3-adrenergic receptor agonists CHAMBERS ROBERT J (US) 2003-10-23 — — US disclosed
WO-2003072547-A1 PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2003-09-04 — — WO disclosed
CN-1387518-A Heterocyclic substituted diphenyl leukotriene antagonists LILLY CO ELI (US) 2002-12-25 — — CN disclosed
US-5877196-A N- 4-(imidazolyl or pyrazolyl)phenyl(oxy, sulfinyl, sulfenyl or sulfonyl)alkyl!carboxamides, sulfonamides or phosphoramides having antiarrhythmic properties AMERICAN CYANAMID COMPANY (US) 1999-03-02 — — US disclosed
EP-0056866-A2 Phenylpiperazine derivatives of heterylphenols and hetarylanilines, their preparation and their pharmaceutical compositions BASF Aktiengesellschaft (DE) 1982-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 MAPT 798/4885ALDH1A1 326/4885POLB 3944/4885
US-20040077871-A1 Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists ADRB3, ADRB1, ADRB2 MAPT 3459/4885ALDH1A1 290/4885POLB 2348/4885
US-20030199046-A1 Processes and intermediates useful in preparing beta3-adrenergic receptor agonists ADRB3, ADRB1, ADRB2 MAPT 3414/4885ALDH1A1 421/4885POLB 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.